Hidden Gallbladder Risks with Popular GLP‑1 Drugs

Glucagon-like peptide‑1 receptor agonists (GLP‑1 RAs), widely used for diabetes and obesity, may be linked to gallbladder inflammation and gallstones. Using FDA adverse event reports from 2004–2024, researchers found a consistent safety signal connecting commonly prescribed GLP‑1 drugs with cholecystitis and cholelithiasis. Most cases occurred in women over 45, typically after several months of treatment. The study reinforces the need for careful monitoring and risk–benefit assessment, especially in patients with existing gallbladder vulnerability

Source : https://pubmed.ncbi.nlm.nih.gov/40697657/